2. Search Result
Search Result
Results for "

weight gain

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Peptides

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3102
    GLP-1(32-36)amide

    		GCGR Metabolic Disease
    GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .
    GLP-1(32-36)amide
  • HY-W015464
    N-Isovaleroylglycine

    		Endogenous Metabolite Metabolic Disease
    N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.
    N-Isovaleroylglycine
  • HY-W015464S
    N-Isovalerylglycine-d9

    		Endogenous Metabolite Metabolic Disease
    N-Isovalerylglycine-d9 is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.
    N-Isovalerylglycine-d9
  • HY-110107
    GW438014A

    		Neuropeptide Y Receptor Metabolic Disease
    GW438014A is a potent and selective NPY-Y5 receptor antagonist. GW438014A inhibits food intake and reduces body weight gain in obese rodents .
    GW438014A
  • HY-145995
    CS12192

    		Others Others
    CS12192 is a compound improving survival and weight gain. CS12192 has the potential for the research of graft-versus-host disease (GVHD) (extracted from the patent CN112773802A) .
    CS12192
  • HY-165393
    Elaidyl-sulfamide

    N-(9E)-9-Octadecen-1-ylsulfamide

    		 PPAR Metabolic Disease
    Elaidyl-sulfamide (N-(9E)-9-Octadecen-1-ylsulfamide) is a PPARα agonist. Elaidyl-sulfamide reduces body weight gain and food intake and reduces circulating cholesterol levels and increases both glucose and insulin levels. Elaidyl-sulfamide has the potential for the research of complicated obesity .
    Elaidyl-sulfamide
  • HY-P3102A
    GLP-1(32-36)amide TFA

    		GCGR Metabolic Disease
    GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .
    GLP-1(32-36)amide TFA
  • HY-W015464S1
    N-Isovaleroylglycine-d2

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    N-Isovaleroylglycine-d2 is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.
    N-Isovaleroylglycine-d2
  • HY-12219B
    MSI-1701

    		Others Metabolic Disease
    MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.
    MSI-1701
  • HY-U00291
    Tauroxicum

    		Antibiotic Infection
    Tauroxicum can be used as a nontoxic, non-antimicrobial agent that can replace or supplement the use of antibiotics in the animal husbandry of livestock animals to increase health and general well-being, productivity, feed efficiency and weight gain.
    Tauroxicum
  • HY-N12169
    Janthitrem A

    11,12-Epoxyjanthitrem B

    		 Others Neurological Disease
    Janthitrem A (11,12-Epoxyjanthitrem B) is a natural product that can be isolated from Penicillium janthinellum. Janthitrem A induces tremors in mice and reduces weight gain and food consumption of porina (Wiseana cervinata) larvae .
    Janthitrem A
  • HY-121827
    LH21

    		Cannabinoid Receptor Metabolic Disease
    LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .
    LH21
  • HY-114520
    TT01001

    		Mitochondrial Metabolism Apoptosis Reactive Oxygen Species Neurological Disease Metabolic Disease
    TT01001 is a potent and orally active mitoNEET ligand. TT01001 reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 improves type II diabetes without causing weight gain .
    TT01001
  • HY-14788
    Drinabant

    AVE1625

    		 Cannabinoid Receptor Metabolic Disease
    Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R .
    Drinabant
  • HY-101699A
    AMG-076

    		MCHR1 (GPR24) Metabolic Disease
    AMG-076 is an orally bioavailable and selective MCHR1 antagonist. AMG-076 results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice .
    AMG-076
  • HY-153617
    FOXO1-IN-3

    		FOXO Metabolic Disease
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
    FOXO1-IN-3
  • HY-130208
    Thiodigalactoside
    3 Publications Verification

    TDG

    		 Galectin Metabolic Disease Inflammation/Immunology Cancer
    Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively . Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats .
    Thiodigalactoside
  • HY-124821
    VA012

    		5-HT Receptor Neurological Disease Metabolic Disease
    VA012 (compound 11) is a positive allosteric modulator (PAM) of the serotonin 5-HT2C receptor. VA012 reduces food intake and body weight gain without causing CNS-related malaise during subchronic administration. VA012 can be utilized in obesity research .
    VA012
  • HY-W042416
    N,N-Dimethylacetamide
    1 Publications Verification

    DMAc

    		 NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .
    N,N-Dimethylacetamide
  • HY-P1306
    Obestatin(rat)

    		GHSR Cardiovascular Disease Inflammation/Immunology
    Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) has anti-inflammatory, anti-myocardial infarction and antioxidant activities .
    Obestatin(rat)
  • HY-P1306A
    Obestatin(rat) TFA

    		GHSR Cardiovascular Disease Inflammation/Immunology
    Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities .
    Obestatin(rat) TFA
  • HY-111254
    GQ-16

    		PPAR Metabolic Disease
    GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a Ki of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain .
    GQ-16
  • HY-122964
    URB447

    		Cannabinoid Receptor Metabolic Disease
    URB447 is a peripherally restricted CB1 cannabinoid antagonist (IC50: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB1-dependent responses. URB447 can be used for research of obesity .
    URB447
  • HY-125091
    LY2066948

    		Estrogen Receptor/ERR Cancer
    LY2066948 is a selective and orally active estrogen receptor modulator (SERM). LY2066948 has high affinity for estrogen receptors ERα and ERβ (Ki: 0.51 and 1.36 nM respectively) and shows potent antiestrogenic activity. LY2066948 blocks uterine weight gain induced by Ethynyl estradiol (HY-B0216) in immature rats. LY2066948 can be used for research of uterine fibroids and myomas .
    LY2066948
  • HY-137307
    Cholest-5-ene-3ß,22(S)-diol

    (22S)-Hydroxycholesterol

    		 Others Inflammation/Immunology
    Cholest-5-ene-3ß,22(S)-diol ((22S)-Hydroxycholesterol) is an orally active oxysterol with no significant cytotoxic, oxidative, or inflammatory effects on human prokaryotic leukemia cells. Cholest-5-ene-3ß,22(S)-diol inhibits weight gain and increased serum triacylglycerol (TAG) levels in rat models .
    Cholest-5-ene-3ß,22(S)-diol
  • HY-124399
    N-Octadecyl-N'-propyl-sulfamide

    		Endogenous Metabolite PPAR Metabolic Disease
    Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.
    N-Octadecyl-N'-propyl-sulfamide
  • HY-101365
    RS-102221

    		5-HT Receptor Neurological Disease
    RS-102221 is a selective 5-HT2C receptor antagonist (Ki=10 nM). RS-102221 shows nearly 100-fold selectivity for the 5-HT2C receptor as compared to the 5-HT2A and 5-HT2B receptors. RS-102221 can promote the differentiation of new nerve cells. RS-102221 increases food-intake and weight-gain in rats .
    RS-102221
  • HY-101365A
    RS-102221 hydrochloride
    1 Publications Verification

    		 5-HT Receptor Neurological Disease
    RS-102221 hydrochloride is a selective 5-HT2C receptor antagonist (Ki=10 nM). RS-102221 hydrochloride shows nearly 100-fold selectivity for the 5-HT2C receptor as compared to the 5-HT2A and 5-HT2B receptors. RS-102221 hydrochloride can promote the differentiation of new nerve cells. RS-102221 hydrochloride increases food-intake and weight-gain in rats .
    RS-102221 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: